Previous 10 | Next 10 |
Provention Bio Announces Publication of Extended Follow-up Data from the Pivotal "At-Risk" TN-10 Study of Teplizumab in Science Translational Medicine -One course of teplizumab delayed insulin dependence by approximately three years and improved beta cell function in at-risk (St...
Provention Bio, Inc. (PRVB) Q4 2020 Earnings Conference Call February 25, 2021 08:00 AM ET Company Participants Robert Doody - Vice President of Investor Relations Ashleigh Palmer - Chief Executive Officer & Co-Founder Jason Hoitt - Chief Commercial Officer Andy Drechsler - Chief Financia...
Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q4 2020 Earnings Call Transcript
Provention Bio (PRVB): Q4 GAAP EPS of -$0.58 misses by $0.07.Cash, cash equivalents and marketable securities of $121.8MPress Release For further details see: Provention Bio EPS misses by $0.07
Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diab...
Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations. Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong. Hangzhou Zhongmei Huadong ...
Provention Bio (PRVB) has announced a partnership with a subsidiary of Huadong Medicine to develop and commercialize PRV-3279 in Greater China. The bispecific antibody-based molecule is currently undergoing development against systemic lupus erythematosus (“SLE”).The agreement w...
Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 - Company also Announces Presentation at the 2021 SVB Leerink Global Healthcare Conference - PR Newswire RED BANK, N.J. , Feb. 18, 2021 /PRNewswire/ -- Prov...
Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China - Provention Bio to receive $6 million upfront payment; up to $11.5 million in research, development and manufacturing funding; and up to $172 million in potential ...
Provention Bio (PRVB) posts positive results from a pre-clinical proof-of-concept study for PRV-3279, a DART (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, conducted in a murine model of gene therapy for Pompe disease.In the study PRV-3279 showed r...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...